Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Background and objectives: Diabetic kidney disease is an important complication of type 2 diabetes. In a phase 2b study, adding esaxerenone to renin-angiotensin system inhibitors dose dependently reduced the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and microalbuminuria. This 52-week phase 3 study further investigated the effects of esaxerenone on the urinary albumin-to-creatinine ratio in this patient group. Design, setting, participants, & measurements: In this multicenter, randomized, double-blind study, patients with type 2 diabetes and a urinary albumin-to-creatinine ratio of 45 to <300 mg/g creatinine treated with renin-angiotensin system inhibitors were randomized to esaxerenone or placebo for 52 weeks ( n =455). Esaxerenone was initiated at 1.25 mg/d and titrated to 2.5 mg/d on the basis of serum potassium monitoring. The primary endpoint was the proportion of patients achieving urinary albumin-to-creatinine ratio remission (<30 mg/g creatinine and ≥30% reduction from baseline on two consecutive occasions). Results: Overall, 49 (22%) and nine (4%) patients in the esaxerenone and placebo groups, respectively, achieved urinary albumin-to-creatinine ratio remission (absolute difference 18%; 95% confidence interval, 12% to 25%; P< 0.001). The percent change in urinary albumin-to-creatinine ratio from baseline to end of treatment was significantly higher with esaxerenone versus placebo (−58% versus 8%; geometric least-squares mean ratio to placebo 0.38, 95% confidence interval, 0.33 to 0.44). There was a significant improvement with esaxerenone versus placebo in time to first remission (hazard ratio, 5.13; 95% confidence interval, 3.27 to 8.04) and time to first transition to urinary albumin-to-creatinine ratio ≥300 mg/g creatinine (hazard ratio, 0.23; 95% confidence interval, 0.11 to 0.48). More patients had a serum potassium level ≥6.0 or ≥5.5 mEq/L on two consecutive measurements in the esaxerenone group (20 [9%]) versus placebo (5 [2%]); these events were asymptomatic and resolved after dosage reduction or treatment discontinuation. Conclusions: Adding esaxerenone to existing renin-angiotensin system inhibitor therapy in patients with type 2 diabetes and microalbuminuria increased the likelihood of albuminuria returning to normal levels, and reduced progression of albuminuria to higher levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Novel nonsteroidal MRA, such as fi nerenone and esaxerenone, are more selective for mineralocorticoid receptors and have been noted to offer similar reductions in albuminuria but with a lower risk of hyperkalemia.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [161]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esaxerenone lowered BP and albuminuria with limited changes in potassium, but long-term studies with clinical end points are lacking (85).”
From Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022) · cites this paper as [85]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Esaxerenone, another ns-MRA, has also been shown to lower urinary albumin excretion.”
The cited source says what the claim attributes to it.
In the citing paper
“However, the long-term kidney and cardiovascular bene fi ts of esaxerenone have not been established, and regulatory approval for esaxerenone is not widespread.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [161]
The cited source says what the claim attributes to it.
In the citing paper
“Similar to fi nerenone, another nonsteroidal MRA, esaxerenone, has also been shown to lower albumin excretion.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [161]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Matsuo, S., Imai, E., Horio, M., Yasuda, Y., Tomita, K., Nitta, K., Yamagata, K., Tomino, Y., Yokoyama, H., & Hishida, A. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.12.034 · Cited by 6,422
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Self-citation
Cited by
Items 101–200 of 246
Lo, K. B., Rangaswami, J., & Vaduganathan, M. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac322 · Cited by 15
Kawaguchi, Y., Hajika, Y., Ashida, N., Rinka, M., Hamai, C., Masumoto, K., Sawa, J., Hamazaki, K., & Kumeda, Y. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100318 · Cited by 12
“In Japanese individuals with T2DM, hypertension, and microalbuminuria, the administration of esaxerenone in combination with an angiotensin-converting enzyme inhibitor (ACE-i) or angiotensin II receptor blocker (ARB) has been shown to increase the rate of reduction or remission of albuminuria [12].”
BackgroundChen, X., Huang, M., Chen, Y., Xu, H., & Wu, M. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10455-1 · Cited by 13
“Among them, esaxeronone (approved for treating arterial hypertension in Japan) and KBP-5074 have significant antihypertensive effects, while finerenone and esaxerenone demonstrate significant renoprotective effects [12, 87–90].”
Annual reports on hypertension research 2020
Mogi, M., Higashi, Y., Bokuda, K., Ichihara, A., Nagata, D., Tanaka, A., Node, K., Nozato, Y., Yamamoto, K. I., Sugimoto, K., et al. (2021) · Hypertension Research · doi:10.1038/s41440-021-00766-3 · Cited by 12
Molecular pharmacology of mineralocorticoid receptor antagonists: The role of co-regulators
Koca, D., & Lother, A. (2023) · Steroids · doi:10.1016/j.steroids.2023.109291 · Cited by 13
Kario, K., Ohishi, M., Katsuya, T., Taguchi, T., Tanabe, A., Sugimoto, K., & Shimosawa, T. (2023) · Journal of Clinical Hypertension · doi:10.1111/jch.14705 · Cited by 12
Kintscher, U. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01998-0 · Cited by 12
“These patients, already on RAS-blockers, were randomly assigned to receive either placebo or esaxerenone at 1.25 mg/day, which could be increased to 2.5 mg/day depending on serum potassium levels [40].”
InfluentialRole of Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Alexandrou, M. E., Theodorakopoulou, M. P., & Sarafidis, P. A. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2020019 · Cited by 13
“5 mg/day or placebo on top of an RAS blocker for 52 weeks [92].”
BackgroundInfluentialChen, Q., Wei, G., Wang, Y., Li, X., Zhao, Q., Zhu, L., Xiao, Q., & Xiong, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1338044 · Cited by 11
Cardiovascular, renal and mortality risk by the KDIGO heatmap in Japan
Maruyama, S., Tanaka, T., Akiyama, H., Hoshino, M., Inokuchi, S., Kaneko, S., Shimamoto, K., & Ozaki, A. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae228 · Cited by 11
Pitt, B., Agarwal, R., Anker, S. D., Rossing, P. R., Ruilope, L. M., Herzog, C. A., Greenberg, B., Pecoits‐Filho, R., Lambelet, M., Lawatscheck, R., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae074 · Cited by 12
Bellos, I., Marinaki, S., Λάγιου, Π., & Benetou, V. (2024) · Biomolecules · doi:10.3390/biom15010039 · Cited by 12
El-fatatry, B. M., El-Haggar, S. M., Ibrahim, O. M., & Shalaby, K. H. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-00995-1 · Cited by 11
Piccirillo, F., Liporace, P., Nusca, A., Nafisio, V., Corlianò, A., Magarò, F., Incalzi, R. A., Ussia, G. P., & Grigioni, F. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10060236 · Cited by 12
“Furthermore, the phase three randomized controlled clinical trial Esaxerenone in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN) showed that adding esaxerenone to RAAS inhibitor therapy in patients with DM and microalbuminuria returned albuminuria to normal levels and reduced its progression [60].”
BackgroundControversies in Hypertension V: Resistant and Refractory Hypertension
Filippone, E. J., Naccarelli, G. V., & Foy, A. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.09.015 · Cited by 14
Chan, A. T. P., & Tang, S. C. W. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.285 · Cited by 12
“Other agents, such as apararenone (phase II study) and esaxerenone (phase III study), were shown to reduce proteinuria (Table 4) [71,72].”
BackgroundAntihypertensive Effects of Esaxerenone in Older Patients with Primary Aldosteronism
Fujimoto, M., Watanabe, S., Igarashi, K., Ruike, Y., Ishiwata, K., Naito, K., Ishida, A., Koshizaka, M., Suzuki, S., Shiko, Y., et al. (2023) · International Journal of Hypertension · doi:10.1155/2023/6453933 · Cited by 10
Innovative therapeutics for renoprotection: Where we are
Cortinovis, M., Perico, N., & Remuzzi, G. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100060 · Cited by 10
Imamura, T., Oshima, A., Narang, N., & Kinugawa, K. (2021) · Circulation Reports · doi:10.1253/circrep.cr-21-0115 · Cited by 10
Novel pharmacological interventions for diabetic kidney disease
Tan, S. K., Pinzón-Cortés, J. A., & Cooper, M. E. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000935 · Cited by 10
Singh, A. K., & Singh, R. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i7.471 · Cited by 13
Finerenona: completando el abordaje del paciente con enfermedad renal y diabetes
Górriz, J. L., González‐Juanatey, J. R., Fácila, L., Soler, M. J., Valle, A., & Ortíz, A. (2022) · Nefrología · doi:10.1016/j.nefro.2022.09.002 · Cited by 15
Aldosterone in Chronic Kidney Disease
Polenus, P., Đuran, A., & Karanović, S. (2025) · Biomedicines · doi:10.3390/biomedicines13092081 · Cited by 11
“These results highlight esaxerenone’s potential as a valuable therapeutic option for the management of diabetic kidney disease [77].”
Babazono, T., Hanai, K., Yokoyama, Y., & Uchiyama, K. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02380-8 · Cited by 10
Mogi, M., Tanaka, A., Node, K., Tomitani, N., Hoshide, S., Narita, K., Nozato, Y., Katsurada, K., Maruhashi, T., Higashi, Y., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01398-5 · Cited by 10
“Administering esaxerenone decreases urinary albumin excretion in patients with type 2 diabetes (ESAX-DN) [132], and Okuda et al. [133] showed that the anti-albuminuric effect is independent of the decrease in blood pressure.”
Negeem, Z. R., Abdel‐Moneim, A., Mahmoud, B., Ahmed, A. E., El-Hameed, A. M. A., Eskandrani, A. A., & Hasona, N. A. (2024) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2024.103975 · Cited by 9
Mineralocorticoid receptor overactivation in diabetes mellitus: role of O-GlcNAc modification
Jo, R., Itoh, H., & Shibata, H. (2024) · Hypertension Research · doi:10.1038/s41440-024-01734-3 · Cited by 10
Sato, A., & Nishimoto, M. (2022) · Hypertension Research · doi:10.1038/s41440-022-00940-1 · Cited by 11
“Based on these trials, the Esaxerenone in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN) study was announced for type 2 diabetic patients with microalbuminuria during RAS inhibitor treatment [52].”
BackgroundDing, K., Li, Z., Lu, Y., & Sun, L. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.05.038 · Cited by 9
Advancements in Pharmacotherapy for Diabetic Kidney Disease: A Systematic Review
Zhang, H., Chen, J., Wang, N., Chen, W., Xu, Y., & Gui, D. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70077 · Cited by 9
Contemporary management of advanced chronic kidney disease: An evidence-based review
Baker, L. W., Ovincy, C., Souvalian, L., Hickson, L. J., & Chebib, F. T. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106557 · Cited by 9
Recent progress in the diagnosis and treatment of primary aldosteronism
Yoshida, Y., & Shibata, H. (2023) · Hypertension Research · doi:10.1038/s41440-023-01288-w · Cited by 8
El-fatatry, B. M., El-Haggar, S. M., Ibrahim, O. M., & Shalaby, K. H. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03804-w · Cited by 8
“Therefore, other treatment options are urgently needed to prevent the progression of DKD [6].”
BackgroundXu, X., Feng, J., Cui, Y., Li, P., Dong, J., & Liao, L. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13566 · Cited by 8
Uchida, H. A., Wada, J., Motoki, H., Kuwahara, K., Kario, K., Katsuya, T., Shimosawa, T., Tsujita, K., Suzuki, S., Suedomi, T., et al. (2025) · Hypertension Research · doi:10.1038/s41440-025-02259-z · Cited by 8
Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
Oshima, A., Imamura, T., Narang, N., & Kinugawa, K. (2021) · Circulation Reports · doi:10.1253/circrep.cr-21-0024 · Cited by 8
Yang, S., Zhao, X., Zhang, J., Liu, H., Wang, Y., & Wang, Y.-G. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1429261 · Cited by 9
“Two RCTs had some concerns for deviations from intended interventions (17, 21), two for missing outcome data (17, 26), one for randomization process (26), one for measurement of the outcome (21), one for selection of the reported result (24).”
BackgroundOhashi, K., Hayashi, T., Utsunomiya, K., & Nishimura, R. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2072730 · Cited by 8
New wrinkles in hypertension management 2022
Carey, R. M., & Whelton, P. K. (2022) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000980 · Cited by 8
Ito, S., Okuda, Y., & Sugimoto, K. (2023) · Advances in Therapy · doi:10.1007/s12325-022-02393-x · Cited by 8
“Factors that were significantly associated with a positive estimated change in office SBP in a sitting position from baseline to 12 weeks after esaxerenone treatment relative to the reference (i.e., these factors may be associated with a weaker BP-lowering effect) included male sex (estimate 4.02 mmHg; p\0.001); highe…”
BackgroundInfluentialSelf-citationSGLT2 Inhibitors and Finerenone: A friendly Duo in the Treatment of Diabetic Kidney Disease?
Asirvatham, A. R., Asirvatham, A. J., & Mahadevan, S. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0759 · Cited by 7
Liu, Z., Lv, R., Guo, H., Zhang, B., Wang, X., Qiang, P., Xiong, Y., Chang, Y., Peng, Y., Hao, J., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114208 · Cited by 7
Rossing, P. R. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab243 · Cited by 8
Motoki, H., Kuwahara, K., Uchida, H. A., Wada, J., Kario, K., Katsuya, T., Shimosawa, T., Tsujita, K., Suzuki, S., Suedomi, T., et al. (2025) · Hypertension Research · doi:10.1038/s41440-025-02347-0 · Cited by 6
Alexandrou, M. E., Theodorakopoulou, M. P., Kanbay, M., & Sarafidis, P. A. (2022) · Journal of Human Hypertension · doi:10.1038/s41371-021-00641-1 · Cited by 7
“[24] and FIGARO-DKD (1.2”
MethodResultInfluentialLiu, Z., Xie, B., Pang, S., Xie, Y., Jili, M., Mo, Z., Li, W., & Yang, R. (2024) · American Journal of Translational Research · doi:10.62347/nrgg6465 · Cited by 6
PREVENTING DIABETIC KIDNEY DISEASE: A SYSTEMATIC REVIEW OF CURRENT PHARMACOLOGICAL APPROACHES
Dharani, B., SEBASTIAN, S., Nazrin, S., & SUBA, A. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i1.52956 · Cited by 6
Renal hemodynamic changes in patients with type 2 diabetes and their clinical impact
Saulnier, P., & Bjornstad, P. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104175 · Cited by 7
Renin Angiotensin Aldosterone System Blockers
Shibata, S., & Fujita, T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00022-0 · Cited by 7
Mineralocorticoid Receptor Antagonists for Diabetic Kidney Disease
Rossing, P. R. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.16201020 · Cited by 6
Efficacy of esaxerenone—a nonsteroidal mineralocorticoid receptor blocker—on nocturnal hypertension
Morimoto, S., & Ichihara, A. (2021) · Hypertension Research · doi:10.1038/s41440-021-00803-1 · Cited by 6
“bitor therapy was shown to further reduce urinary albumin excretion without affecting renal function in patients with type 2 diabetes and microalbuminuria [6].”
BackgroundNaami, R., Miller, D. M., Datla, S., Rahman, M. U., Al-Kindi, S. G., & Neeland, I. J. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000746 · Cited by 5
Soe, K. K., & Selvarajah, D. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.101149 · Cited by 6
“Esaxer-enone, has been shown to lower albumin excretion 89,90 , although its long-term kidney and cardiovascular benefits remain unestablished.”
Emerging Medical Therapies for Primary Aldosteronism
Vibhatavata, P., & Turcu, A. F. (2026) · Hypertension · doi:10.1161/hypertensionaha.126.26229 · Cited by 5
Low Density Lipoprotein Apheresis for Treatment of Focal Segmental Glomerulosclerosis
Dawson, M., Ghose, S., Abdelnour, N., Shah, R., Sreenivas, A., Vala, K. B., Sethi, S. K., & Raina, R. (2025) · Hemodialysis International · doi:10.1111/hdi.13208 · Cited by 5
Ros, M. L., Aguilar-Gallardo, J. S., Shah, A., Narasimhan, B., & Aronow, W. S. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2138744 · Cited by 5
Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease
Watson, K., Kukin, A., Wasik, A., & Shulenberger, C. E. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000990 · Cited by 5
Tamura, K., Kanaoka, T., Fujiwara, N., & Hirota, K. (2023) · Hypertension Research · doi:10.1038/s41440-023-01338-3 · Cited by 5
Tatsugawa, R., Kidokoro, K., Iwakura, T., Hirano, A., Kajimoto, E., Takasu, M., Wada, M., Kitao, H., Wada, Y., Gyarmati, G., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf232 · Cited by 4
“Furthermore, an increase in eGFR and urinary albumin excretion was observed after discontinuation of the MRA [6 ].”
Self-citationKitao, T., Konishi, E., Itoh, N., & Hirata, A. (2024) · Circulation Reports · doi:10.1253/circrep.cr-24-0142 · Cited by 4
Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT
Hobbs, R. F., McManus, R. J., Taylor, C. J., Jones, N. R., Rahman, J. K., Wolstenholme, J. L., Jones, L., Hirst, J. A., Mort, S., & Yu, L. (2025) · Health Technology Assessment · doi:10.3310/pyft6977 · Cited by 4
Management of Diabetes in Patients with Chronic Kidney Disease
Ambalavanan, J., & Caramori, M. L. (2025) · Endocrine Research · doi:10.1080/07435800.2025.2473896 · Cited by 5
“31 Esaxerenone 32 another agent in this class, has also been shown to lower albumi-nuria and blood pressure in patients with type 2 diabetes and microalbuminuria, however data from large randomized clinical trials are not yet available.”
Pharmacotherapy for mild hypertension
Wang, D., Wright, J. M., Adams, S. P., Cundiff, D. K., Gueyffier, F., Grenet, G., & Ambasta, A. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006742.pub3 · Cited by 4
Yoshihara, K., Fukae, M., Kastrissios, H., Wada, R., Shimizu, T., & Ishizuka, H. (2023) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2023.100516 · Cited by 4
Yoshihara, K., Fukae, M., Kastrissios, H., Wada, R., & Shimizu, T. (2023) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2023.100535 · Cited by 4
Bakris, G. L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15617 · Cited by 4
“50,54,55,58 Thus, while all classes of MRAs will raise potassium, the question is one of magnitude and management.”
InfluentialHuart, J., & Jouret, F. (2025) · Kidney and Blood Pressure Research · doi:10.1159/000545286 · Cited by 3
“This agent has demonstrated ef fi cacy in reducing proteinuria in T2DM and BP in hypertensive patients with a tolerable safety pro fi le [6, 41 – 43].”
Esaxerenone inhibits renal macrophage proliferation through MR/TGF-β1 pathway in db/db mice
Yang, F., Liu, Z., Li, Y., Lv, R., Zhao, Y., FanYang, Shimosawa, T., Tan, J., Xu, Q., & Qiang, P. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.124008 · Cited by 3
Nakamura, M., Satoh, N., Mizuno, T., Takagi, M., Horita, S., & Nangaku, M. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1677518 · Cited by 3
Self-citationOhishi, M., Kario, K., Katsuya, T., Shimosawa, T., Shiosakai, K., Furugori, T., Taguchi, T., & on behalf of the EXCITE-HT investigators (2025) · Hypertension Research · doi:10.1038/s41440-025-02437-z · Cited by 3
Yoshida, Y., & Shibata, H. (2026) · Hypertension Research · doi:10.1038/s41440-026-02561-4 · Cited by 3
Nugroho, P. (2025) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303350851241021105850 · Cited by 4
Rossing, P. R., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2481-2004 · Cited by 3
“Die behördliche Zulassung von Esaxerenon ist bislang auf die Behandlung von Bluthochdruck in Japan beschränkt [28, 29].”
Pliças, M. M. D., da Silva, B. M., & Almeida, E. (2025) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2025.02.010 · Cited by 3
Kamrul-Hasan, A. B. M., Mondal, S., Nagendra, L., Dutta, D., Bhattacharya, S., & Pappachan, J. M. (2025) · Medicine · doi:10.1097/md.0000000000043615 · Cited by 3
“[23] The retrospective cohort study lasted 36 months.”
Doggrell, S. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1904892 · Cited by 3
“In subjects with type 2 diabetes and microalbuminuria, esaxerenone improved kidney function and decreased blood pressure [12].”
BackgroundKurata, A., Eto, T., Tsutsumi, J., Igawa, Y., Nishikawa, Y., & Ishizuka, H. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1087 · Cited by 3
Zhu, L., & Shi, P. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-04059-9 · Cited by 2
“The reported incidence of hyperkalemia varied among studies, with 18.3% in the FIDELIO-DKD study, 10.8% in the FIGARO-DKD study and 9% in the ESAX-DN study [29].”
InfluentialAdvancing Cardiorenal Interaction: From Pathophysiological Paradigms to Novel Therapeutic Strategies
Wei, L., He, P., Gao, J., Huang, L., Zhao, L., Zhang, R., Ning, X., & Sun, S. (2025) · Kidney Diseases · doi:10.1159/000548367 · Cited by 2
“In the ESAX-DN study, esaxerenone reduced albuminuria in patients with T2D, but more patients discontinued it due to hyperkalemia [91].”
Erzeel, J., Es, M. V., Müllens, W., & Martens, P. (2026) · Current Heart Failure Reports · doi:10.1007/s11897-026-00740-5 · Cited by 2
“However, this is a Current Heart Failure Reports (2026) 23:5 mg/g) was achieved significantly more in the esaxerone group (22% versus 4% in placebo; absolute difference 18%; 95% CI 12–25%; p < 0.001) [65].”
InfluentialKanki, M., Vivekanantham, E., Tesch, G. H., Parslow, A. C., Cole, T. J., Fuller, P. J., Donner, D. G., Kiriazis, H., de Haan, J. B., Sun, J. M., et al. (2026) · Endocrinology · doi:10.1210/endocr/bqaf178 · Cited by 2
Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease
Mottl, A. K., Khunti, K., & Mathieu, C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70587 · Cited by 2
“108 In addition, results from two single-arm dose escalation studies showed effective BP lowering effects with esaxere-none in hypertensive patients with moderate kidney dysfunction without diabetes.”
Pharmacotherapy for mild hypertension
Wang, D., Wright, J. M., Adams, S. P., Cundiff, D. K., Gueyffier, F., Grenet, G., & Ambasta, A. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006742.pub4 · Cited by 3
Aldosterone synthase inhibitors: a new option for antihypertensive, cardio-renal protection
Sato, A., & Nishimoto, M. (2026) · Hypertension Research · doi:10.1038/s41440-026-02671-z · Cited by 2
“Hypertension and organ damage caused by an inappropriate balance between aldosterone and salt are deeply involved in pathologies such as chronic heart failure, chronic kidney disease (CKD), and vascular disorders [1 – 7].”
Drugs to Slow Progression of Chronic Kidney Disease: It Is a Whole New World!
Schoonmaker, J. A., Bhasin-Chhabra, B., Alkhier, A. A., Swaminathan, S., & Hommos, M. S. (2026) · Kidney & Blood Pressure Research · doi:10.1159/000552776 · Cited by 2
Targeting the Renin-Angiotensin-Aldosterone System: Preclinical and Clinical Developments
Steckelings, U. M., Rossitto, G., & Bäder, M. (2026) · Circulation Research · doi:10.1161/circresaha.126.327681 · Cited by 3
Management of hypertension in advanced kidney disease
Georgianos, P. I., & Agarwal, R. (2022) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000812 · Cited by 2
Revisiting Hypertension Treatment in Patients With Chronic Kidney Disease
Hernandez, M. R. F., & Chang, T. I. (2024) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2024.151514 · Cited by 3
Focus on Finerenone, a Non-Steroidal MRA in Diabetic Kidney Disease. What Physicians Should Know?
Chakraborty, D. S., Choudhury, S., & Lahiry, S. (2022) · Medicina Moderna - Modern Medicine · doi:10.31689/rmm.2021.29.1.25 · Cited by 2
Novel pharmacologic approaches in resistant hypertension
Głuszek, J. (2024) · Wiadomości Lekarskie · doi:10.36740/wlek/194090 · Cited by 3
“Recently, the efficacy and safety of a new aldosterone receptor antagonist called esaxerenone [18,19] was assessed in Japan.”
Lessons learned from early-stage clinical trials for diabetic nephropathy
Rendell, M. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2326025 · Cited by 1
“Given the recent success of finerenone, several pharmaceutical companies have pursued investigational agents in this class including esaxerenone and apareronone [80,81].”
BackgroundAttachaipanich, T., Kaewboot, K., & Attachaipanich, S. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2530842 · Cited by 1
Esaxerenone Attenuates Atherogenesis and Vascular Dysfunction in Apolipoprotein E-Deficient Mice
Maeda, J., Munkhjargal, U., Hara, T., Bavuu, O., Fukuda, D., & Sata, M. (2025) · International Heart Journal · doi:10.1536/ihj.25-051 · Cited by 1
Nuclear receptors as therapeutic targets in metabolic and cardiovascular disorders
Li, F., Chen, Q., Dai, Y., & Lu, L. (2025) · iScience · doi:10.1016/j.isci.2025.114042 · Cited by 1
Neue Hemmstoffe des RAAS für die Blutdrucksenkung
Müller, M., & Stegbauer, J. (2025) · Die Nephrologie · doi:10.1007/s11560-025-00886-8 · Cited by 1
Fan, Q., Qin, G., Du, B., Kan, M., Li, M., Li, Q., & Zhang, Z. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109236 · Cited by 2
Hara, R., Yamahara, H., Hirakawa, Y., Hashiba, T., Keying, H., Tabata, H., & Nangaku, M. (2026) · Nephrology · doi:10.1111/nep.70176 · Cited by 1
“Urine samples were obtained from participants enrolled in the ESAX-DN study, a randomised, double-blind, placebo-controlled clinical trial [9, 10].”
Self-citationGembillo, G., Visconti, L., Tranchida, V., Nardi, C., Calimeri, S., Gambuzza, M. E., Princiotto, M., Chinigò, C., Soraci, L., & Santoro, D. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i4.115058 · Cited by 2
Gîrdan, L., Gavris, C. M., & Nedelcu, L. D. (2024) · Jurnal Medical Brasovean · doi:10.31926/jmb.2023.1.4 · Cited by 1
“Și esaxerenona și -a demonstrat efectul nefroprotector, cu o incidență a hiperpotasemiei de 9% (Ito S et al., 2020) .”
BackgroundJeong, G.-H. (2026) · Diabetology · doi:10.3390/diabetology7050084 · Cited by 1
Metadata
- Authors
- Ito, S., Kashihara, N., Shikata, K., Nangaku, M., Wada, T., Okuda, Y., & Sawanobori, T.
- Affiliations
- Tohoku University (JP)
- Kawasaki Medical School (JP)
- Okayama University Hospital (JP)
- The University of Tokyo (JP)
- Kanazawa University (JP)
- Daiichi-Sankyo (Japan) (JP)
- Corresponding author
- Ito, Sadayoshi
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2020-11-25
- Volume
- 15
- Issue
- 12
- Pages
- 1715-1727
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- PMC
- PMC7769030
- OpenAlex
- W3107151441
- Cited by
- 234
- References
- 42
- Citations by year
- 2026: 30 · 2025: 40 · 2024: 46 · 2023: 46 · 2022: 46 · 2021: 25 · 2020: 1
- FWCI
- 18.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Daiichi Sankyo Co., Ltd
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- One, type 2 diabetes, microalbuminuria, diabetic nephropathy, albumin-creatinine ratio, renin-angiotensin system inhibitors, mineralocorticoid receptor antagonists, serum potassium, renal protection, hospitalization
- MeSH terms
- Aged, Albuminuria, Mineralocorticoid Receptor Antagonists, Creatinine, Diabetes Mellitus, Type 2, Female, Humans, Japan, Kidney, Male, Middle Aged, Pyrroles, Remission Induction, Risk Factors, Sulfones, Time Factors, Biomarkers, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.